Crude incidence and risk of mycobacterial infection among RA patients who were new users of TNFI or non-biological DMARD
| Exposures | Events | Person-years | Crude rate (per 1000 person-years) | Adjusted HR* |
|---|---|---|---|---|
| Tuberculosis | ||||
| Non-biological DMARD | 1 | 6980 | 0.1 (0.0, 1.0) | 1.00 (Reference) |
| New users of TNFI | 8 | 22 275 | 0.4 (0.2, 0.7) | 4.2 (0.5, 33.5) |
| Non-tuberculous mycobacteria | ||||
| Non-biological DMARD | 4 | 6981 | 0.6 (0.2, 1.5) | 1.00 (Reference) |
| New users of TNFI | 10 | 22 272 | 0.4 (0.2, 0.8) | 0.9 (0.3. 3.3) |
*Adjusted by propensity score quintile. Estimates were stratified by site and all 95% CI were based on robust SE.
DMARD, disease-modifying anti rheumatic drug; RA, rheumatoid arthritis; TNFI, tumour necrosis factor α inhibitors.